Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: How to speed it up?

Giuseppe Curigliano, Carmen Criscitiello, Fabrice Andrè, Marco Colleoni, Angelo Di Leo

Research output: Contribution to journalArticle

Abstract

The recognition that early breast cancer is a spectrum of diseases each requiring a specific systemic therapy guided the 13th St Gallen International Breast Cancer Consensus Conference [1]. The meeting assembled 3600 participants from nearly 90 countries worldwide. Educational content has been centred on the primary and multidisciplinary treatment approach of early breast cancer. The meeting culminated on the final day, with the St Gallen Breast Cancer Treatment Consensus, established by 40-50 of the world's most experienced opinion leaders in the field of breast cancer treatment. The major issue that arose during the consensus conference was the increasing gap between what is theoretically feasible in patient risk stratification, in treatment, and in daily practice management. We need to find new paths to access innovations to clinical research and daily practice. To ensure that continued innovation meets the needs of patients, the therapeutic alliance between patients and academic-led research should to be extended to include relevant pharmaceutical companies and drug regulators with a unique effort to bring innovation into clinical practice. We need to bring together major players from the world of breast cancer research to map out a coordinated strategy on an international scale, to address the disease fragmentation, to share financial resources, and to integrate scientific data. The final goal will be to improve access to an affordable, best standard of care for all patients in each country.

Original languageEnglish
Article number299
Journalecancermedicalscience
Volume7
Issue number1
DOIs
Publication statusPublished - Mar 26 2013

Fingerprint

Breast Neoplasms
Therapeutics
Research
Practice Management
Standard of Care
Pharmaceutical Preparations

Keywords

  • 13th St Gallen Consensus Conference 2013
  • Early Breast Cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{ddb6452e240444c980a23988ec692473,
title = "Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: How to speed it up?",
abstract = "The recognition that early breast cancer is a spectrum of diseases each requiring a specific systemic therapy guided the 13th St Gallen International Breast Cancer Consensus Conference [1]. The meeting assembled 3600 participants from nearly 90 countries worldwide. Educational content has been centred on the primary and multidisciplinary treatment approach of early breast cancer. The meeting culminated on the final day, with the St Gallen Breast Cancer Treatment Consensus, established by 40-50 of the world's most experienced opinion leaders in the field of breast cancer treatment. The major issue that arose during the consensus conference was the increasing gap between what is theoretically feasible in patient risk stratification, in treatment, and in daily practice management. We need to find new paths to access innovations to clinical research and daily practice. To ensure that continued innovation meets the needs of patients, the therapeutic alliance between patients and academic-led research should to be extended to include relevant pharmaceutical companies and drug regulators with a unique effort to bring innovation into clinical practice. We need to bring together major players from the world of breast cancer research to map out a coordinated strategy on an international scale, to address the disease fragmentation, to share financial resources, and to integrate scientific data. The final goal will be to improve access to an affordable, best standard of care for all patients in each country.",
keywords = "13th St Gallen Consensus Conference 2013, Early Breast Cancer",
author = "Giuseppe Curigliano and Carmen Criscitiello and Fabrice Andr{\`e} and Marco Colleoni and {Di Leo}, Angelo",
year = "2013",
month = "3",
day = "26",
doi = "10.3332/ecancer.2013.299",
language = "English",
volume = "7",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",
number = "1",

}

TY - JOUR

T1 - Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer

T2 - How to speed it up?

AU - Curigliano, Giuseppe

AU - Criscitiello, Carmen

AU - Andrè, Fabrice

AU - Colleoni, Marco

AU - Di Leo, Angelo

PY - 2013/3/26

Y1 - 2013/3/26

N2 - The recognition that early breast cancer is a spectrum of diseases each requiring a specific systemic therapy guided the 13th St Gallen International Breast Cancer Consensus Conference [1]. The meeting assembled 3600 participants from nearly 90 countries worldwide. Educational content has been centred on the primary and multidisciplinary treatment approach of early breast cancer. The meeting culminated on the final day, with the St Gallen Breast Cancer Treatment Consensus, established by 40-50 of the world's most experienced opinion leaders in the field of breast cancer treatment. The major issue that arose during the consensus conference was the increasing gap between what is theoretically feasible in patient risk stratification, in treatment, and in daily practice management. We need to find new paths to access innovations to clinical research and daily practice. To ensure that continued innovation meets the needs of patients, the therapeutic alliance between patients and academic-led research should to be extended to include relevant pharmaceutical companies and drug regulators with a unique effort to bring innovation into clinical practice. We need to bring together major players from the world of breast cancer research to map out a coordinated strategy on an international scale, to address the disease fragmentation, to share financial resources, and to integrate scientific data. The final goal will be to improve access to an affordable, best standard of care for all patients in each country.

AB - The recognition that early breast cancer is a spectrum of diseases each requiring a specific systemic therapy guided the 13th St Gallen International Breast Cancer Consensus Conference [1]. The meeting assembled 3600 participants from nearly 90 countries worldwide. Educational content has been centred on the primary and multidisciplinary treatment approach of early breast cancer. The meeting culminated on the final day, with the St Gallen Breast Cancer Treatment Consensus, established by 40-50 of the world's most experienced opinion leaders in the field of breast cancer treatment. The major issue that arose during the consensus conference was the increasing gap between what is theoretically feasible in patient risk stratification, in treatment, and in daily practice management. We need to find new paths to access innovations to clinical research and daily practice. To ensure that continued innovation meets the needs of patients, the therapeutic alliance between patients and academic-led research should to be extended to include relevant pharmaceutical companies and drug regulators with a unique effort to bring innovation into clinical practice. We need to bring together major players from the world of breast cancer research to map out a coordinated strategy on an international scale, to address the disease fragmentation, to share financial resources, and to integrate scientific data. The final goal will be to improve access to an affordable, best standard of care for all patients in each country.

KW - 13th St Gallen Consensus Conference 2013

KW - Early Breast Cancer

UR - http://www.scopus.com/inward/record.url?scp=84876376364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876376364&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2013.299

DO - 10.3332/ecancer.2013.299

M3 - Article

C2 - 23589728

AN - SCOPUS:84876376364

VL - 7

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

IS - 1

M1 - 299

ER -